Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone206-325-6086
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees4
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Atossa Genetics (NASDAQ:ATOS) Frequently Asked Questions
What is Atossa Genetics' stock symbol?
Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS."
When did Atossa Genetics' stock split? How did Atossa Genetics' stock split work?
Atossa Genetics's stock reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Genetics stock prior to the reverse split would have 8 shares after the split.
How were Atossa Genetics' earnings last quarter?
Atossa Genetics Inc (NASDAQ:ATOS) issued its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.32. View Atossa Genetics' Earnings History.
When is Atossa Genetics' next earnings date?
What price target have analysts set for ATOS?
1 brokers have issued 1-year price targets for Atossa Genetics' stock. Their forecasts range from $9.00 to $9.00. On average, they expect Atossa Genetics' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 423.9% from the stock's current price. View Analyst Price Targets for Atossa Genetics.
What is the consensus analysts' recommendation for Atossa Genetics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Genetics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Atossa Genetics.
Has Atossa Genetics been receiving favorable news coverage?
Headlines about ATOS stock have trended negative this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Atossa Genetics earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Atossa Genetics.
Are investors shorting Atossa Genetics?
Atossa Genetics saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 221,200 shares, a drop of 19.2% from the August 30th total of 273,800 shares. Based on an average daily volume of 135,400 shares, the short-interest ratio is presently 1.6 days. Currently, 2.4% of the company's shares are short sold. View Atossa Genetics' Current Options Chain.
Who are some of Atossa Genetics' key competitors?
Some companies that are related to Atossa Genetics include Apollo Endosurgery (APEN), Pro-Dex (PDEX), AIT Therapeutics (AITB), STRATA Skin Sciences (SSKN), BeyondAirInc . (XAIR), Motus GI (MOTS), Nephros (NEPHD), Invo Bioscience (IVOB), Arch Therapeutics (ARTH), SANUWAVE Health (SNWV), Interpace Diagnostics Group (IDXG), PAVmed (PAVM), Neovasc (NVCN), Titan Medical (TMDI) and Nuvectra (NVTR).
What other stocks do shareholders of Atossa Genetics own?
Who are Atossa Genetics' key executives?
Atossa Genetics' management team includes the folowing people:
- Dr. Steven C. Quay, Chairman, CEO & Pres (Age 68)
- Mr. Kyle Guse CPA, Esq., CPA, CFO, Gen. Counsel & Sec. (Age 55)
- Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical Affairs
- Dr. Jack Cuzick, Member of Scientific Advisory Board
How do I buy shares of Atossa Genetics?
Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Atossa Genetics' stock price today?
One share of ATOS stock can currently be purchased for approximately $1.72.
How big of a company is Atossa Genetics?
Atossa Genetics has a market capitalization of $15.68 million. The company earns $-11,400,000.00 in net income (profit) each year or ($5.50) on an earnings per share basis. Atossa Genetics employs 4 workers across the globe.View Additional Information About Atossa Genetics.
What is Atossa Genetics' official website?
How can I contact Atossa Genetics?
Atossa Genetics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected]
MarketBeat Community Rating for Atossa Genetics (NASDAQ ATOS)
MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote "Outperform" if you believe ATOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
